Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens? EXPERT REVIEW OF ANTI-INFECTIVE THERAPY Nafisi, S., Roy, S., Gish, R., Manch, R., Kohli, A. 2016; 14 (1): 41-56

Abstract

This review summarizes published data on sofosbuvir-based regimens for patients infected with HCV GT1 with a focus on evaluating the optimal and possible durations of treatment.PubMed and conference abstract books published between 2011-2015 were searched.HCV treatment has decreased from 24 week regimens to studies done as short as 4 weeks. History of prior treatment or cirrhosis have consistently shown lower SVR12 rates with shorter duration therapies. Low cure rates have been seen in patients within 4 week trials, however, select patients with low fibrosis scores, low HCV VL and HCV GT-1b have moderate cure rates.Most patients will require 12-24 weeks of therapy. Further studies are needed to elucidate the predictors of treatment response to short duration therapies and optimal combination of DAAs.

View details for DOI 10.1586/14787210.2016.1114883

View details for Web of Science ID 000367830100002

View details for PubMedID 26654939